Ms. Hemrajani has served as a member of our board of directors since April 2020. She is currently the Chief Executive Officer and Director of Jiya Acquisition Corporation. She has previously served as President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company, Chief Operating Officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company and Chief Financial Officer and Senior Vice President of Business and Financial Operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), a biotechnology company. Ms. Hemrajani was also Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen) and Vice President of Business Development at Exelixis. She started her career in healthcare investment banking at Credit Suisse First Boston and Lehman Brothers. Ms. Hemrajani currently serves as a director at MaxCyte and previously served as a director at Adverum Biotechnologies, Inc. and Aravive. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.